Some health conditions require alternatives to using dry, oil, wax, or edible medical cannabis.

Here are four new methods for patients to absorb medical cannabis.

Cannabinoids have demonstrated tremendous potential in treating many medical conditions, ranging from epilepsy to chronic pain. The problem is that many of these conditions rely on cannabinoids passing through the blood-brain barrier, while others require rapid absorption into the bloodstream. Conventional delivery systems are not ideally suited to achieve these goals, which has prompted many companies to develop alternatives.

In this article, we will look at four alternative delivery systems for cannabinoids and why investors may want to consider the companies behind them.

1. Oral Thin Films

Listerine® PocketPack® and other breath strips have become a popular way to kill bad breath germs in less than 30 seconds. It turns out that the same type of technology could help efficiently deliver cannabinoids into the bloodstream without the use of water.

CURE Pharmaceutical Corp. (OTCQB: CURR) is developing an oral thin film technology with faster onset and greater bioavailability than tablets and other conventional delivery systems. Using a micro-encapsulation process, the active ingredients are shielded by phospholipids and liposomes to deliver higher doses with better flavor masking. These active ingredients bypass the gastric system and are rapidly absorbed into the bloodstream for maximum effectiveness.

Since they’re simply placed the tongue to dissolve, oral thin films are ideally suited for children and elderly patients that may have trouble swallowing pills. They may also help improve compliance since they don’t require water and have improved flavor masking.

2. Chewing Gum

GlaxoSmithKline’s (NYSE: GSK) Nicorette® chewing gum has become the most popular nicotine replacement therapy in the world. But surprisingly, chewing gum hasn’t been used as a delivery mechanism for many other drugs despite its convenience and benefits.

AXIM Biotechnologies Inc. (OTCQB: AXIM) is developing chewing gum-based cannabinoid therapies targeting a wide range of medical conditions. The company’s most advanced program is CanChew Plus® for the treatment of irritable bowel syndrome (“IBS”), but it has similar programs targeting multiple sclerosis / pain spasticity, Parkinson’s disease, dementia, restless leg’s syndrome, opioid addiction, tobacco smoking cessation, and other conditions.

In addition to effectively delivering cannabinoids into the blood stream, chewing gum offers a controlled release via cellulose and may improve cerebral circulation, stimulate the basal ganglia, reduce stress, improve memory, and offer neuroprotective benefits.  

3. Lipid Encapsulation

The primary issue with tablets and other swallowed medicine is that they’re subject to so-called first pass metabolism. Compounding this problem, studies have shown that cannabinoids do not tolerate acidic environments like the stomach.

Lexaria Corp. (OTCQB: LXRP) is developing lipid encapsulation technologies designed to protect cannabinoids in acidic environments and maximize absorption. The company’s researchers processed a mixture of hemp oil, black tea, and select lipids to create a cannabinoid-infused tea that has resulted in as much as a 499% increase in intestinal tissue permeability for cannabidiol (“CBD”) over a concentration matched mixture of just CBD and water.

In addition to improved bioavailability, the company’s licensable technology platform has a rapid onset of just 15-20 minutes – compared to 60-120 minutes for conventional therapies – along with the elimination of undesirable tastes. The company has already signed several licensing agreements to commercialize the patented technology around the world. Lexaria is working with the Canadian federal government, through the National Research Council, on further research, development, and commercialization opportunities.

4. Sol-Gel Nasal Delivery

Soft gels have become a popular delivery mechanism since they are easy to administer, familiar to patients, and may contain a variety of different chemicals designed for slow-release and other features that improve the safety and efficacy profile of the active ingredients.

PreveCeutical Medical Inc.’s (CNSX: PREV) Sol-Gel technology encapsulates cannabinoids in a soluble form, while nanomicelles provide tissue permeation enhancing properties. Local tissue irritation is avoided as cannabinoids are in-solution and can be presented at lower doses. At the same time, Sol-Gels can remain in place for extended periods of time, which can reduce the administration times to once or twice weekly rather than daily.

The company has pioneered a novel process for preparing insoluble drug-containing nanomicelles and incorporating them into Sol-Gels in conjunction with the Parekh group at PACE-UQ. The team plans to file a provisional patent application around the single phase Sol-Gels for nasal delivery, which could vastly improve bioavailability relative to other therapeutics that are already on the market.

Looking Ahead

Cannabinoids have tremendous potential in addressing many medical conditions, but there are some unique challenges to their absorption. Fortunately, there are many companies working on improved delivery systems designed to increase bioavailability, reduce the onset time, and improve the taste profile and other convenience factors. Investors may want to take a look at these companies as potential investment opportunities in the space.

This article by Ryan Allway originally appeared on www.cannabisfn.com.

The post Four New Ways for Patients to Use Medical Cannabis appeared first on .

Brightfield Group and HelloMD teamed up for a report on CBD oil user experience, anticipating that the total cannabidiol market will reach $467 million in 2017.

“Sales of marijuana-derived CBD are expected to hit $176 million and hemp-derived CBD will hit $291 million in 2017, according to Brightfield Group data.

The survey included 2,400 HelloMD medicinal cannabis community members from the United States (primarily California) and abroad.

“CBD, known for the medical relief it provides for a plethora of conditions without the psychoactive effects or “high” caused by THC, makes up a growing part of the cannabis market,” according to the report.

Notable results of the survey included:

• 58 percent of CBD-only users are women.
• 42 percent of CBD users have stopped using traditional medicine and use cannabis instead.
• About 66% of CBD users indicated that CBD products are either “more effective” or “much more effective” in relieving their medical conditions than are over-the-counter products.
• Top medical conditions treated by CBD include joint pain, insomnia, depression and anxiety.

Users reported that pros of using CBD products included medical relief and medication without the psychoactive effects of THC. Cons included pricing and availability.

Research has indicated that CBD protects the brain cells from harm in neurodegenerative diseases.

The effect of CBD on epilepsy influenced the recent legalization of medical cannabis in Mexico. CBD can reduce seizures in epilepsy the same way that it can moderate other chemicals found in the brain.

The post Report: Nearly Half of CBD Oil Patients Stop Using Traditional Medications appeared first on .

THC comes to mind when a lot of people talk about cannabis, but CBD is getting quite renowned due to its beneficial effects on the body. As scientific research moves step by step forward every day, it becomes clear that every medical cannabis strain has its own properties. CBD helps the brain in an intricate and pertinent manner. There is no psychoactive effect attached to CBD. This makes it different from THC which has some psychoactive effects. This happens because CB1 receptors are not activated by cannabidiol. The manner by which cannabidiol affects the brain shall be explained further.

It has relevant antipsychotic properties

CBD has antipsychotic effects that are just like the ones for amisulpride. The recent trend is that more and more people prefer CBD due to the fact that it doesn’t have as much side effects as amisulpride. The antipsychotic effects of CBD stem from the effect it has on anandamide that is increased in the brain because of the presence of cannabinoids. A reduction in psychotic related symptoms has been connected to increased levels of anandamide in the brain.

It protects the brain cells from harm in neurodegenerative diseases

Research has indicated that CBD can keep the brain cells away from damage. This reduces the inflammatory response that the immune system produces. Chemokines, cytokines and other inflammatory molecules that are found at the sites of inflammation are then reduced. When various brain injuries from animal models were examined, it was found out that CBD boosted a number of viable brain cells. It also decreased the number of brain cells that were damaged by more than half. This shows that CBD can decrease the injury to the brain caused by traumas. CBD can also block pain signals that are sent to the brain by decreasing inflammation through peripheral means. Ointments that contain CBD reduced sudden pains and inflammation of the joints. Therefore, it is perfect for treating pain caused by arthritis. Chemical compounds of marijuana and marijuana itself are perfect for protecting the cells of the brain from neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease, and other dementia forms.

It helps with depression and anxiety

CBD can prevent compounds like THC from binding to CB1 receptors by interacting with the receptors in a specific manner. CBD can also cure a lot of problems caused by THC like memory problems and anxiety. CBD interacts with a serotonin receptor that relates directly to depression symptoms. It has also been seen that regions that get hyperactive during anxiety disorders can be calmed by CBD. CBD does this by decreasing flow of blood to the areas of the brain like the hypothalamus that are connected with anxiety. The general anxiety scores of those who partook in the study were decreased. CBD can also work as an antidepressant which is unique from its function as an anxiety reducer. For depressed people, CBD can create a balance in the impairment of their endocannabinoid system. In a study, imaging scans were used by researchers to understand the brain regions that are involved with the anti-anxiety effects of CBD. This has created new ways of curing depression. Although conventional medications that use to cure depression have side effects, CBD has none.

It can be used to treat epilepsy

The effect of CBD on epilepsy has created a lot of buzz and has led to huge progress in the cure for epilepsy. CBD can reduce seizures in epilepsy the same way that it can moderate other chemicals found in the brain. CBD can prohibit mechanisms of the brain that contribute to seizures by increasing the release of GABA, the inhibitory neurotransmitter. Charlotte Figi is the most popular case of CBD being used to cure epilepsy.

The post CBD and Your Brain appeared first on .

Things are about to change for Washington medical marijuana patients. Once recreational adult-use became legal, legislators recognized that something needed to be done to reconcile the medical and recreational programs. Last year, on April 24, the Governor signed into law SB 5052, better known as The Cannabis Patient Protection ACT (CPPA), coming into full effect on July 1.

The bill is an attempt by legislators to provide clarity on what constitutes medical use, while making sure qualified patients can obtain a sufficient amount of medical marijuana consistently and safely.

What issues does it seek to solve?

First and foremost, the new law codifies a regulatory structure for medical marijuana by marrying it to the more regulated recreational program, specifically:

• Providing consumer protections
• Revising the taxing code
• Shifting oversight of the program from the Department of Health to the Washington State Liquor and Cannabis Board — in effect, merging the programs

What issues will it potentially create?

Americans for Safe Access (ASA) wasn’t happy with the proposed law and worked hard to pass an alternate bill, House Bill 2058. They mobilized advocates to petition the government to pass the alternate bill which they believe would have ensured licensing and oversight would occur within a dedicated framework designed specifically to protect qualifying patients.

Restricts Patient Access

Until the law soon goes into effect, medical patients — registered through the Department of Health — have been permitted to grow their own plants. With the new law in effect, patients could lose their ability to purchase clones, specific products, and strains they found most beneficial. This could include concentrates, high THC content edibles, and high CBD strains. They may also see a rise in their medical costs.

Community Doesn’t Like “Optional” Patient Database

Also, of concern is that patients will see their possession and cultivation limits reduced, unless they register in a government database. Critics argue the database violates patient privacy and could expose patients to criminal liability. Many in the medical marijuana community contend that compelling patients to register to access sufficient amounts of medication is essentially forcing them to admit to committing a federal crime and that disclosure of personal medical details violates privacy protections under Health Insurance Portability and Accountability Act (HIPAA).

Governor Inslee disagrees, and has sought to alleviate concerns on an FAQ page his office established. According to the Governor‘s office, “Privacy will be ensured at the highest possible level, and the database does not in any way violate HIPPA.” The Bill’s sponsor, Sen. Ann Rivers, contends the database is important so regulators can ensure there are enough stores providing medical cannabis to patients.

Collectives

According to the Governor’s office, “The legislation allows cooperative gardens and requires the Liquor and Cannabis Board (LCB) to increase the maximum number of marijuana retail outlets.” Patients — up to four — can form a their own cooperative garden. They may cultivate and possess up to sixty plants and 72 ounces of usable cannabis.

Dispensaries

The LCB will issue licenses to medical marijuana dispensaries who meet “reasonable criteria.” What’s reasonable, you say?

• A collective garden operator must be 21 years or older, has maintained a business license, has an established history of paying pertinent taxes, and doesn’t have a criminal history
• The dispensary can’t be located in proximity to schools, playgrounds or other similar buildings.

Retail licensees are permitted to sell recreational marijuana, only medical marijuana or both.

As is usually the case when the government enacts new measures, they’ll fix some things, while creating other issues people find problematic. Hopefully, legislators and the Liquor and Cannabis Board will resolve outstanding issues as soon as possible so that those most in need of medical cannabis won’t have to sacrifice protections or access.

Gov. Inslee maintains he’s committed to ironing out any issues that come. According to the Governor, “[T]o the extent further changes may be necessary to ensure a patient-focused, well run medical marijuana system, we’ll be able to do that in future legislative sessions.”

Adam Schmidt of Clear Choice Cannabis, a Tacoma, Washington-based recreational dispensary is upbeat about the changes:

Whenever there are changes to existing laws, there are going to be some growing pains, but we support the the new law and also plan to continue serving medical cannabis patients.” Schmidt continues, “We feel confident that Governor Inslee and state legislators will be responsive to the community and committed to ironing out any kinks that may arise.

The post What You Need To Know About Washington’s Cannabis Patient Protection Act appeared first on .

In an unusually warm December, the medical cannabis advocacy organization Americans for Safe Access were joined by the Minister of Health for the Czech Republic, Svatopluk Němeček to announce the establishment of a new research center, the International Cannabis and Cannabinoid Institute (ICCI) – intended to foster evidence-based exploration with a modern scientific approach to refine the therapeutic applicability of cannabis-based medicines in the Czech Republic. 

Run in conjunction with KOPAC, a patient’s organization that was formed to pass and implement medical cannabis laws in the Czech Republic, and Dioscorides Global Holdings (DGH), a New York-based investment platform focused on the emerging legal cannabis industry, ICCI will identify, coordinate and support global research priorities for the advancement of cannabinoid treatments through a multidisciplinary evidence-based approach that incorporates the most innovative tools and approaches.

The work of the ICCI will remove barriers to access for patients globally by bringing together the current knowledge base for cannabis research as it relates to biomedicine, life sciences and policy sciences to create a platform for sharing, exploration and education.

“As a medical cannabis patient who has been benefiting from it use for 14 years, I have felt a responsibility to ensure that other patients in the US, and now globally, have the choice to utilize cannabis treatments,” said Steph Sherer, executive director of Americans for Safe Access. “The creation of the ICCI is an integral step in fulfilling that commitment. The work of the ICCI will remove barriers to access for patients globally by bringing together the current knowledge base for cannabis research as it relates to biomedicine, life sciences and policy sciences to create a platform for sharing, exploration and education.”

New scientific and medical research has revealed many health and therapeutic benefits of cannabis in the decades since it was first included in the 1961 UN Convention on Narcotic Drugs Schedule IV list of restricted drugs. In the arena of cannabis research, scientists have observed both the therapeutic effects and safety profile in diverse patient groups who have already received cannabis as a part of clinical trials. These findings have been challenging to investigate due to an array of circumstances such as the international criminalization of the cannabis plant, scarcity of available research institutions, and lack of funding.

Despite these hurdles, millions of people are finding relief using cannabis treatments for an array of medical conditions and symptoms. Currently, two-thirds of the US population live in states with medical cannabis laws, and over 2 million Americans currently use medical cannabis as a treatment option. Canada, Israel, Netherlands, Czech Republic, Croatia, Mexico, Uruguay, Romania, Germany, Jamaica, Australia, Colombia, and Switzerland all have national medical cannabis programs, while dozens of other countries are in the process of reviewing legislation.

The purpose is to enable scientific examination of the relation between bioactive cannabis compounds and the effect on the human organism in the treatment of specific syndromes and, in the future, systemic health disorders.

“The main work of the ICCI is to provide scientific instruments to public and private institutions all over the world. The purpose is to enable scientific examination of the relation between bioactive cannabis compounds and the effect on the human organism in the treatment of specific syndromes and, in the future, systemic health disorders,” said the ICCI CEO Pavel Kubů.

As an international collaborative project of nonprofit, for-profit, and government institutions, ICCI has developed strategic project partnership alliances with participation from Universities, Hi-Tech Companies, and Institutions from around the globe and will become an international research and educational hub designed to meet the needs of patients globally.  ICCI is connecting a cross-disciplinary approach that captures the current knowledge base across the fields of biomedical research, social science, life sciences, and policy research  with the sole purpose of identifying and resolving barriers to advancements.  The results are to be shared across academia, research institutes, private endowments, governments, medical professional, patient advocacy organizations, health service providers, and product manufacturers.

The buy-in from the top tier Czech medical institutions is unprecedented.

“We knew we wanted to invest in science-based cannabis research. The remarkable work being done by Americans for Safe Access – and their sister group KOPAC in Prague – has made it possible for this work to exist in the correct legal framework. The buy-in from the top tier Czech medical institutions is unprecedented.  We are excited to have these institutions, scientists, doctors, researchers and government leaders on board with our mission.  This is the single best place and group of people with whom to launch the ICCI, and I am confident this institution will inform and advance how the world perceives and applies cannabis-based medicines,” said Ben Bronfman, Founder of DGH.

With over 100,000 active members in all 50 states, Americans for Safe Access is the largest national member-based organization of patients, medical professionals, scientists and concerned citizens promoting safe and legal access to cannabis for therapeutic use and research. They work to overcome political and legal barriers by creating policies that improve access to medical cannabis for patients and researchers through legislation, education, litigation, grassroots actions, advocacy and services for patients and the caregivers.

It seems the mild weather was not the only warm reception. See below a report on the announcement on Czech news.

The post Americans for Safe Access, Czech Universities launch international cannabis research centre appeared first on .

As the medical cannabis landscape in California heats up, industry leaders are working on new and innovative solutions to provide Californians with not just medicine, but access to medical consultations as well. One such company, Eaze, is going a step further and is offering medical cannabis recommendations via any mobile device on their new platform EazeMD.

Launched in July of 2014, Eaze is a technology company headquartered in San Francisco and committed to providing the easiest, quickest and most professional medical cannabis delivery to patients across California. Currently operating in more than 100 cities between San Francisco and San Diego, Eaze is the first-to-market, largest, and most funded cannabis delivery solution.

Introducing EazeMD: Physician Recommendations On Demand

After creating a successful technology solution to connect patients with dispensaries, CEO Keith McCarty sought to improve access to medical cannabis consultations. Launched in July of this year, EazeMD allows California patients to video chat with physicians via www.eaze.md on demand from the comfort of home. With no scheduling required, and at the most affordable rate of $30, patients can now get their recommendation and medicine in as little as 30 minutes.

For the first time ever, medical cannabis patients can now download the EazeMD app on iTunes or the Google Play store and be connected with a physician in minutes. Built from the ground up – EazeMD follows the strictest HIPAA compliance standards, including use of encryption technology to ensure patient privacy.

A Look Back

When the on-demand technology space began to heat up in 2012, tech veteran Keith McCarty took a look at what made the space successful. There were “three pillars” which seemed to indicate success of an on-demand service: frequency of use, ability to be agile on the supply side, and finally – there needed to be an inherently social aspect.

Around this time, a study revealed that for the first time ever, a majority of Americans were in favor of cannabis legalization. After reading the story of Charlotte Figi, a 6 year old child who suffered from Dravet Syndrome and when treated with cannabis experienced a significant reduction in frequency of seizures, McCarty realized medical cannabis would be the perfect industry to benefit from on-demand technology. After curating a world class team of engineers, Eaze launched to bring patients and dispensaries together more conveniently and efficiently than ever before.

Eaze’s advanced routing algorithm enables dispensary drivers to deliver medicine on the most efficient route possible, reducing delivery times to about 15 minutes or less. This is crucial for patients like Jessica Smith* who suffers from crippling migraines which last over 10 hours on average.

“I have about 30 minutes where I can feel the migraine coming on and need to take high CBD medicine to prevent it. Eaze has saved me on a number of occasions when I was out and didn’t have any medication on me. I was able to pull up the app, order the medicine and have it delivered directly to me in under 15 minutes.” -Jessica Smith, medical cannabis patient.

Who benefits from EazeMD?

Amanda and hundreds of other patients who face accessibility issues can now also benefit significantly the two solutions provided by Eaze and now EazeMD. A common myth around medical cannabis recommendations is about the existence of a government list for all patients with recommendations, when in actuality, record of patients recommendations is protected under federal law through HIPAA and cannot be accessed, similar to any other medical documents you may have. EazeMD provides the most secure telehealth video conferencing, and at the most accessible price point of $30. For patients interested in the EazeMD process, they’d simply fill out a short medical history and evaluation form, and are then immediately connected with a board certified physician to be evaluated. No appointments necessary. If approved, the patient is instantly routed to the Eaze menu where they are able to order their medication.

The addition of EazeMD to the Apple and Google Play app stores marks a historic moment for the cannabis industry as the first to marry technology, medical cannabis and telehealth into a single, simple, beautiful application.

**Names have been altered to protect patient privacy

The post EazeMD Launches First Telehealth Application for iOS & Android appeared first on .

Last week Medical Marijuana, Inc. (OTC Pink: MJNA) announced that its flagship product Real Scientific Hemp Oil (RSHO) has again made world history as the first cannabis product to be approved on a case-by-case basis for Parkinson’s disease by the Brazilian Government Health Agency ANVISA, which is responsible for approving citizen importation of medicines not found in Brazil.

Following Epilepsy (CDKL5 and Dravet Syndrome), which was the first indication to be approved, Parkinson’s Disease becomes the second approved indication of Medical Marijuana, Inc.’s RSHO by Brazil’s ANVISA for importation with medical recommendation. Medical Marijuana, Inc. and its partner company HempMeds Brasil are working diligently within the framework of the Brazilian Government for approvals of at least five other indications.

Brazil Approves RSHO For Parkinson’s Treatment

MJNA’s partner HempMeds Brasil is providing the RSHO exclusively for the Brazilian marketplace while under temporary case-by-case approval for several additional medical indications, subject to clinical trials within the country.

Today, any resident of Brazil who has a government-approved medical indication and who would like to have access to RSHO hemp oil products, may do so with a doctor’s prognosis, prescription and government-approved import documentation. ANVISA has issued a statement on the agency’s website and has also made an effort to explain how to apply for an import certificate. HempMeds Brasil has been working for over a year on its formal product application and regulatory submission. The company expects this process to be completed by the end of 2015.

Brazilian Orlando Mesquita is battling Parkinson’s and has been taking RSHO for the past four weeks. Mesquita says he is, “sleeping better and my movements are much more fluid and controlled.” In that short period of time, Mesquita’s wife has already noticed a 50% improvement with her husband’s medical condition.

The government of Brazil, with their 1988 Constitutional right of free health care (SUS) to all citizens, is again leading the way by putting the well-being of their people first. RSHO products have been provisionally approved and are being reviewed for potentially six other medical indications, which are subject to future clinical trials. – Stuart W. Titus, PhD – CEO of Medical Marijuana, Inc.  

In 2005, the number of Parkinson’s patients worldwide was between 4.1 and 4.6 million. By the year 2030, those numbers are expected to more than double to 8.7 and 9.3 million patients according to the European Parkinson’s Disease Association. The Parkinson’s Disease foundation states that, in the U.S. alone, Parkinson’s is estimated to cost nearly $25 billion every year in combined direct and indirect costs.

Hemp is widely regarded as a superfood and MJNA’s cannabidiol (CBD) hemp oil is derived from the mature stalk of the hemp plant and is considered a food nutrient delivering the benefits of cannabinoids without the psychotropic/euphoric effects of THC. Although CBD hemp oil products are readily available in America, hemp oil products are handled quite differently in Brazil.

Until recently, the Brazilian government treated anything derived from cannabis, including hemp, as an illegal controlled substance. However, in a series of landmark rulings, the Brazilian government began permitting the importation of hemp CBD oil products with registration by the Federal government agency ANVISA. The Federal government agency also removed CBD from its prohibited substance use list.

What do you think about Brazil’s decision to allow medical hemp treatments for Parkinson’s disease? Join the conversation and comment below!

The post Brazil Approves Medical Hemp RSHO For Parkinson’s Treatment appeared first on .

At a time when metabolic syndrome presents a significant public health issue in society, an analysis of the National Health and Nutrition Examination Survey (NHANES) indicates that cannabis consumption could provide relief. Metabolic syndrome, a combination of symptoms including high blood pressure, diabetes, and obesity, is a contributing factor to cardiovascular illness and can be potentially fatal. According to the original NHANES report, metabolic syndrome continues to be a pervasive problem in the U.S.

However, according to the analysis conducted by the University of Miami Leonard M. Miller School of Medicine, recently published by the American Journal of Medicine, reveals individuals who consume cannabis — even in a smokable form — are approximately 50 percent less likely to have metabolic syndrome than those who have never used cannabis.

This may seem ironic as historically, the popular narrative is to portray cannabis users as lazy, munchie-obsessed slackers, who lead a sedentary lifestyle, leading many to assume that cannabis users would be more inclined to acquire metabolic syndrome. However, research suggests just the opposite.

Results from the National Health and Nutrition Examination Survey (NHANES) Analysis

The University of Miami Leonard M. Miller School of Medicine examined data gathered between 2005 and 2010 to determine if there was a correlation between marijuana use and metabolic syndrome. The researchers analyzed data from the National Health and Nutrition Examination Surveys consisting of approximately 8500 subjects between the ages of 20 and 59 years old, who were considered afflicted by metabolic syndrome based on the following criteria — they must have three or more of the following:

• Elevated fasting glucose levels
• High triglycerides
• Low HDL cholesterol
• Elevated systolic
• Diastolic blood pressure
• Increased waist circumference

The researchers segmented subjects into three categories:

• Those who have never consumed cannabis
• Those who currently consume cannabis
• Those who have consumed cannabis, but have stopped

Key Findings

• Researchers determined 19.5% of the participants in the study who had never consumed cannabis met the criteria of metabolic syndrome.
• Of former cannabis users, 17.5% could be diagnosed with metabolic syndrome.
• Most surprisingly, current cannabis users were the least significant group affected by metabolic syndrome, at just 13.8%
• Cannabis users indicated average glucose levels (how much sugar is present in one’s blood). These levels were significantly lower compared to people who never consumed cannabis.
• Cannabis users also demonstrated fasting glucose levels at significantly lower levels when compared to people who never used and their waist circumference was significantly lower among men who currently smoked.

Julie Holland, MD, psychopharmacologist, winner of the Norman Zinberg Award for Medical Excellence in 2011 and author of “The Pot Book: A Complete Guide to Cannabis“, has come to similar conclusions cited in the study: “What reverses insulin resistance? Cannabis. It turns out that the cannabinoid system is intimately involved in sugar and energy utilization.” Julie Holland, MD, continues, “Chronic pot smokers have smaller waistlines, better cholesterol and fatty acid levels, and less insulin resistance than people who don’t use the drug.”

Further, in Dr. Holland’s research, she found the endocannabinoid system is crucial to maintaining one’s metabolism. Likewise, she concludes insulin sensitivity and resistance are crucial when it comes to weight management.

How Prevalent is Metabolic Syndrome? 

According to key findings of the original study National Health and Nutrition Examination Survey (NHANES), although the U.S. obesity epidemic has stabilized, metabolic syndrome continues to be a major problem.

Key findings from NHANES:

• Nearly 35 percent of all U.S. adults and 50 percent of those 60 years of age or older were estimated to have the metabolic syndrome in 2011-2012.
• From 2003-2004 to 2011-2012, the overall prevalence of the metabolic syndrome increased from 32.9 percent to 34.7 percent.
• From 2003 to 2012, prevalence was higher in women compared with men.
• When stratified by race/ethnicity, the highest prevalence was seen in Hispanics, followed by non-Hispanic whites and blacks.
• Prevalence increased by age groups, increasing from 18.3 percent among those 20 to 39 years of age to 46.7 percent among those 60 years or older.

The prevalence of metabolic syndrome among older populations is particularly concerning. Dr. Robert Wong, an assistant clinical professor at University of California, San Francisco and senior author of the study believes the high prevalence among the oldest age group is concerning because, “We know the population of the U.S. is aging. I think it will potentially place a huge burden on our health care system.”

University of Miami Leonard M. Miller School of Medicine’s Study Is Good News for Society

Could the results from analysis be good news for not only the legal cannabis reform movement but for society as a whole? Certainly.

With immense health costs and an aging population, it is imperative that policymakers understand the prevalence and problems of metabolic syndrome so that they can create policies to fight against it. The study provides further ammunition for sensible policy makers to advance liberalization of cannabis laws and expand access to medical marijuana. Further, policy makers could use evidence from the study to expand the list of treatable ailments that medical marijuana can treat.

The Bottom Line

According to authors of the University of Miami Leonard M. Miller School of Medicine analysis of the NHANES study: “Current marijuana use is associated with lower odds of metabolic syndrome across emerging and middle-aged US adults. Future studies should examine the biological pathways of this relationship.”

The researchers added, “These findings have important implications for the nation as marijuana use becomes more accepted and we simultaneously face multiple epidemics of obesity, cardiovascular disease, and diabetes.”

What are your thoughts on this subject? How do you think research like this is moving the medical cannabis conversation forward? Join the conversation and comment below!

Additional Sources:

• National Institutes of Health
• U.S. National Library of Medicine: Metabolic Syndrome among Marijuana Users in the United States: An Analysis of National Health and Nutrition Examination Survey Data
• Journal of the American Medical Association: Prevalence of the Metabolic Syndrome in the United States, 2003-2012
• Julie Holland, M.D.: “Moody Bitches, The Truth About the Drugs You’re Taking, The Sleep You’re Missing, The Sex You’re Not Having, and What’s Really Making You Crazy”, page 173
• T. C. Kirkham, “Endocannabinoids in the° Regulation of Appetite and Body Weight,” Behavioral Pharmacology 16, no. 5–6 (2005): 297–313
• Yann Le Strat and Bernard Le Foll, “Obesity and Cannabis Use: Results from 2 Representative National Surveys,” American Journal of Epidemiology 174, no. 8 (2011): 929
• Elizabeth A. Penner et al., “The Impact of Marijuana Use on Glucose, Insulin, and Insulin Resistance Among U.S. Adults,” American Journal of Medicine 126, no. 7 (2013): 583–89

The post Cannabis Lowers Blood Pressure and Diabetes Risk appeared first on .

When it comes to cannabis business and policy, the state of Colorado sits under a metaphorical microscope.

Nearly two years have passed since the first legal flowers were sold in the state, rightly drawing interest from states like California who are looking to write policies of their own. What kinds of issues remain post-legalization? From experiments in limited social use measures to allow consumption in Denver bars and restaurants, to the various ways in which the medical and recreational cannabis businesses are regulated differently, there is much for cannabis industry professionals to explore and learn from.

Some recent proposals are garnering attention in Colorado right now that deserve a mention:

A new proposed policy by the Colorado Medical Board would require cannabis-recommending doctors to suggest the possibility of serious side effects, including death, to medical patients before prescribing medical cannabis. Though the recreational market is strong in Colorado, there are still around 106,000 medical card holders who would be affected by this policy when it comes time to renew their doctors’ recommendations.

Among other concerning parts of the proposal, this policy could hypothetically harm the medical cannabis industry. It’s likely that, indirectly, this is being proposed for tax reasons. In Colorado, recreational cannabis retail sales are taxed, while dispensary sales are not. By making recommendations harder to obtain, pushing patients out of the medical cannabis system and into the recreational market, the state would eventually increase its intake of tax revenues. However, there’s also the chance that those who declined to renew their recommendations would simply go back to the black market or become home growers, again bypassing the taxed market.

Brett Roper, Director of Licensing Services at Medicine Man Technologies in Denver, has a more optimistic outlook and says that this change is just a sign of the times.

“Disclaimers seem to have become a regular part of our everyday lives…from cigarette and drug packaging; to car reminders to wear seat belts warning of dismemberment, death and other maladies; to warnings on most everything we purchase,” commented Roper. “I strongly suspect that the medical patient prescriptive process will not be significantly impacted by further disclaimers, which we as a society have become somewhat immune to, and do not expect this to dampen our business outlook or client decision making process.”

Retaining a solid medical cannabis program in Colorado is important for underrepresented groups like the chronically ill, the poor, and the elderly. Should new disclaimer policies do their job in scaring off potential patients and those in need of renewal, the medical cannabis sector will likely fade away. Even if they’re not creeped out by the potential side effects, these individuals may not be able to afford an in-depth exam or pass scrutiny under the proposed strict policies, and will head to the recreational market.

Proposition BB, to be posted on the November ballot, will let voters decide whether excess tax revenue from cannabis should be returned to taxpayers or spent by the state on things like education and law enforcement.

In 2014, tax revenues from cannabis so far exceeded the cap set by the state regulations, that every citizen of Colorado is set to receive his or her share of $58 million in tax refund. While that’s absolutely amazing, the state could benefit from the extra cash as well, and if the populace is ready to continue prioritizing educational gains in the state, the voters may choose to waive their refund for the greater good. If the measure fails, the difference will be made up by lowering the cannabis sales tax.

What does a Denver insider think about the Proposition?

“As Brett Roper, taxpayer: I would certainly like to see the excess collections be allocated for the public good, in particular schools and law enforcement. However, in all fairness, it would also seem logical that those paying the excess taxes be the beneficiary of any such refund process. So just call me conflicted.”

Seems that Colorado voters have a tough decision on their hands.

Covering relevant policy news is important to us, and we can’t be everywhere at once. To refer any news or local policy concerns to our editorial team for consideration, please contact us and we’ll do our best to respond.

The post Colorado Cannabis Policy Update appeared first on .

On Friday, Americans For Safe Access announced that the Medical Marijuana Regulation and Safety Act was signed into law by Governor Jerry Brown. The new policy, formerly known in the California legislature as AB 266, AB 243, and SB 643, regulates the medical cannabis industry from seed to sale for the very first time since the state passed legislation allowing medical cannabis 20 years ago.

The 70-page package of bills was painstakingly crafted in conjunction with the Governor’s office, so it was expected by many to pass no matter what, but the official signature brings a new era of legitimacy for California cannabis businesses. Another notable supporter, Lt. Gov. and 2018 gubernatorial candidate Gavin Newsom, said that “Given the history and complexity of California’s market, achieving the people’s will and responsibly regulating marijuana will be a process that unfolds over many years, requiring sustained attention to implementation.”

Newsom is right; there are already groups positing that some portions of the new law illegally amend corresponding portions of the original Prop 215 legislation, including the 10’x10′ canopy allowance for at-home cultivation. Nonetheless, a licensed and regulated medical cannabis landscape will lay the groundwork for the possibility of further adult use regulations after the 2016 general election.

Below is the full text of the announcement from ASA.

Veronica —

California Governor Jerry Brown just signed three bills that will license and regulate commercial medical cannabis cultivation, manufacturing, distribution, transportation, sales, and testing in the state. The bills become law on January 1st, nineteen years after voters approved Proposition 215 and called on lawmakers to implement a plan for safe and legal access in the state.

Click here to read my blog about the Medical Marijuana Regulation and Safety Act, important victories for patients in the bills, and what still needs improvement.

ASA has been working to adopt state licensing and regulation of medical cannabis since 2012 because we know that sensible regulations preserve access for patients, while reducing crime and complaints in communities. We are proud to say that years of persistent and pragmatic advocacy have paid off. These bills represent an important milestone in a long campaign to fully implement Proposition 215.

I am going to be talking about the bills and what comes next in a live Google Hangout next week. A Google Hangout is an interactive online event your can join from your computer of mobile device.

What:  What’s Next for Medical Cannabis… Regulation, Legalization, and More

When:Thursday, October 15, at 8:00 PM Pacific

Where:

Click on the link a few minutes before 8:00 PM. You may need to install some free software to ask questions or make comments. You can watch the event live on YouTube without installing software, but you will not be able to use the interactive features.

Please join me on Thursday and invite your friends!

Sincerely,

Don Duncan
California Director

Americans for Safe Access

What does this mean for new and existing medical cannabis cultivators, manufacturers, retailers, and everyone in between? Check out the Cashinbis analysis of AB 266 for an overview of some of the new requirements for doing business in the Golden State.

The post California MMJ Regulations Signed Into Law: AB 266, AB 243, and SB 643 appeared first on .

]]> https://cashinbis.com/california-mmj-regulations-signed-into-law/feed/ 0 https://cashinbis.com/weedy-com-cannabis-education-for-the-baby-boomer-generation/ https://cashinbis.com/weedy-com-cannabis-education-for-the-baby-boomer-generation/#respond Wed, 23 Sep 2015 13:00:08 +0000 https://cashinbis.com/?p=6421

While access to cannabis varies from state to state, one thing is for certain: people from all walks of life – and a variety...

The post Weedy.com: Cannabis Education for the Baby Boomer Generation appeared first on .

]]>

While access to cannabis varies from state to state, one thing is for certain: people from all walks of life – and a variety of age groups – are starting to become more interested in the cannabis plant as a mainstream medical substance.

In a 2013 Gallup Poll, 44% of adults between ages 50 and 64 reported using cannabis, up from just 9% surveyed in 1985. To provide in-demand services to this demographic, Weedy.com is the newest website solution for dispensary discovery, specifically catering to the cannabis needs of the baby-boomer generation.

Prospective medical cannabis patients can sign on to Weedy, locate a clinic to obtain a doctor’s recommendation, and at the same time locate a great dispensary in the area as well as a smoke shop to purchase the necessary accessories. It’s a user-friendly platform with a clean design and little to no display ads, making it perfectly navigable for the over-50 crowd.

Most of Weedy’s business listings are in California, but they have end users and business profiles in all states where medical cannabis is legal, and their goal is to reach the entire United States.

Platform With A Purpose

Weedy is the first software platform released by Silicon Valley-based Green Web Services, Inc., founded by Ryan Hunt, Charlyn McNamara, Trang Nguyen and Noosphere Ventures. Focused on consumer education, Weedy allows users to search for local doctors, strains, dispensaries, and smoke shops from any location where medical cannabis is legal under state law.

For more than a century, medical cannabis has been stigmatized in the United States, especially amongst baby boomers who experienced drug war propaganda firsthand. This education-based platform fills a void in the industry by counteracting a trend of misinformation among a key demographic of patients. The lack of consumer education within the medical cannabis space only continues to perpetuate the negative stigma surrounding people who choose to consume cannabis.

Weedy not only connects patients to doctors, dispensaries and head shops in their area; it also provides in-depth strain reviews and information for various ailments, as well as friendly and easily digestible YouTube videos that break down specifics about various consumption methods, how to shop for your medicine, and more.

The Issue

Sites such as Weedmaps and Leafly have served the mainstream medical cannabis market for some time, but with their complicated search features, loud and colorful design, and overwhelming array of display ads, these sites can be intimidating to your mom, dad, or grandparent seeking basic information online. That’s why founder Ryan Hunt knew that this generation needed a new and different channel tailored specifically to their needs.

“Boomers are an untapped market, especially for the cannabis industry…70 percent of disposable income in the US comes from this group. The baby boomer demographic is turning to cannabis for 3 key reasons: pain management, rising health costs, and simply living in an empty nest where they can be free to use cannabis again.” – Ryan Hunt – Founder of Weedy.com

The newly-launched company welcomes patients, doctors, and cannabis educators to explore Weedy.com as a lifestyle resource and learn about the ways medical cannabis might benefit their lives.

If you are a dispensary or glass shop owner, make sure you’ve got your Weedy business listing set up as well, or you’ll be missing out on exposure to this vital group of consumers.

The post Weedy.com: Cannabis Education for the Baby Boomer Generation appeared first on .

]]> https://cashinbis.com/weedy-com-cannabis-education-for-the-baby-boomer-generation/feed/ 0 https://cashinbis.com/kannalife-sciences-announces-publication-of-global-patent/ https://cashinbis.com/kannalife-sciences-announces-publication-of-global-patent/#respond Tue, 11 Aug 2015 21:30:58 +0000 https://cashinbis.com/?p=5770

Kannalife Sciences Discusses Orphan Drug Opportunity For New ‘Super CBD’ Molecule Kannalife Sciences, Inc. has announced its intentions to pursue an orphan drug opportunity...

The post Kannalife Sciences Announces Publication of Global Patent appeared first on .

]]>

Kannalife Sciences Discusses Orphan Drug Opportunity For New ‘Super CBD’ Molecule

Kannalife Sciences, Inc. has announced its intentions to pursue an orphan drug opportunity for a new ‘Super CBD’ molecule listed as KLS-13019. This new molecule is a Novel Functionalized 1,3-Benzene Diol for the treatment of Hepatic Encephalopathy (HE). HE is a brain disorder associated with individuals who have developed liver disease. KLS-13019 aims to block negative toxins from reaching the brain, a process that would represent the biggest innovation in the history of HE treatment. It is estimated that 1.5Mil people in the Unites States alone suffer from Hepatic Encephalopathy, with approximately 200,000 of them suffering from a more serious, grade three classification. Such a classification qualifies HE as an orphan (rare) disease. By developing KLS-13019, an orphan drug to treat an orphan disease, Kannalife’s new molecule can be fast tracked through the FDA’s approval process and, if approved, will be granted seven years of exclusivity, in accordance to FDA orphan drug regulations.

Who is KannaLife Sciences, Inc.?

Founded in 2010, Kannalife Sciences, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife began their research looking to work with cannabinoids to create better and more efficient medical treatments. Kannalife chose to work primarily with CBD and, after considering the wide range of effective applications, they chose to primarily focus on the development of brain disease treatments. Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy (“HE”) and Chronic Traumatic Encephalopathy (“CTE”). HE and CTE are oxidative stress related diseases that affect cognitive and behavioral functions.

What is Hepatic Encephalopathy?

Hepatic encephalopathy, or HE, is a brain disorder that develops in some individuals with liver disease. HE is characterized by personality changes, intellectual impairment, and a depressed level of consciousness. The development of hepatic encephalopathy is explained, to some extent, by the effect of neurotoxic substances, which occurs in the setting of cirrhosis and portal hypertension. Kannalife’s newly developed, CBD-like molecule aims to stop toxic substances like these from ever reaching the brain. Successful application could mean a decrease in overall drug consumption, in addition to a healthier intestinal system, as patients suffering from HE often take ten or more prescription pills per day.

“Our pre-clinical studies using cannabidiol (CBD) as a positive control, side-by-side with KLS-13019 and other cannabidiol-like molecules of this class, reveals dramatic potency and safety improvements for this novel chemotype. Kannalife’s patent application further describes the novel chemotype useful as neuroprotective agents in the treatment of diseases associated with hepatic encephalopathy. KLS-13019 demonstrated improved oral bioavailability and CNS penetration relative to CBD and bodes well for its ability to penetrate the blood brain barrier, ameliorate brain toxicities associated with HE, and address unmet medical needs”. – Dean Petkanas, CEO of Kannalife.  

The Super CBD Goal

KLS-13019 is the official designation that has been given to this newly developed molecule. The molecule will be renamed once it has moved further down the process to becoming an FDA approved drug. This ‘Super CBD’ is ~295 times less toxic than its naturally occurring CBD counterpart. In effect, KLS-13019 blocks unwanted toxins, that directly lead to HE, from reaching the brain. Other medications designed to help treat HE encourage the patient to filter out toxins through their stomach. The overall goal of this new ‘CBD-like’ molecule is to provide a much safer and reliable method to combat HE. Currently, a patient who suffers from HE could take as many as 10 pills in a ‘cocktail’ like treatment, with each pill containing its own side effects and impact on the intestinal system. If successful, this new molecule could replace the majority of pills used to properly treat HE, creating a healthier patient.

“In 2010 we believed there was an opportunity to build upon the promising preclinical findings with CBD in HE and design a novel cannabidiol-like therapeutic agent that would have benefits in terms of therapeutic index and delivery by the oral route. Developing our New Chemical Entity via the orphan status pathway will provide advantages in terms of reduced development cost and greater exclusivity in the marketplace.” – Dean Petkanas, CEO of Kannalife.  

What is an Orphan Drug?

The FDA’s new drug application process allows for priority review as it pertains to orphan drugs designed to treat orphan diseases. Priority review is designed to expedite programs on new drug applications for serious conditions. Orphan status grants seven years exclusivity. It is estimated that there are 1.5 million sufferers of hepatic encephalopathy (HE) in the US, of which, approximately 200,000 patients suffer from overt hepatic encephalopathy (Grade 3), representing an orphan drug opportunity for a novel drug in use.

Orphan status allows the FDA to fast track the development and application of new treatments due to the smaller patient population associated with orphan diseases (also known as rare diseases). Once the new drug is approved, a seven year exclusivity period is granted to the discovering entity. Without orphan drug status, the FDA approval process is much longer and, unless a patent is filed, exclusivity is not a factor. Furthermore, because CBD is a natural substance, it is not patentable. By creating a molecule that is ‘CBD-like’, Kannalife has created a patentable product that is ~295 times less toxic than its natural CBD counterpart.

What happens next?

Kannalife Sciences, Inc. is continuing to develop and test KLS-13019 as they work towards FDA approval and the eventual market entrance of this new drug. In addition to the treatment of HE, Kannalife is using CBD to develop a treatment for CTE, a disease that is synonymous with concussions, especially pertaining to contact sports like football, and has been brought to the public’s attention by Dr. Bennett Omalu. Dr. Omalu is on the scientific advisory board at Kannalife and was the first to identify Chronic Traumatic Encephalopathy (CTE) in pro-football players.

The Hepatic Encephalopathy Market

Xifaxan®, produced by Salix Pharmaceuticals, is one of the chemical treatments that Kannalife is aiming to enhance or replace with their new drug. According to a report by Credit Suisse, Xifaxan® sales to treat Hepatic Encephalopathy accounted for roughly 70% of total Salix sales. Those sales are estimated to deliver approximately $900Mil in 2015 with estimates driving towards $1.4Bil by 2018.

Kannalife is a major investment portfolio company of Medical Marijuana, Inc. (MJNA) which owns a little over 16% of the company. For more information on Hepatic Encephalopathy click the link here.

The post Kannalife Sciences Announces Publication of Global Patent appeared first on .

]]> https://cashinbis.com/kannalife-sciences-announces-publication-of-global-patent/feed/ 0